

LocoMMotion Final Analysis

Table S3: TEAEs reported in ≥5% of patients in index LOT.^a

TEAE	Total (N = 248)	
	Any grade, n (%)	Grade 3/4, n (%)
Hematologic TEAE	124 (50.0)	101 (40.7)
Thrombocytopenia	65 (26.2)	48 (19.4)
Anemia	64 (25.8)	27 (10.9)
Neutropenia	50 (20.2)	43 (17.3)
Leukopenia	22 (8.9)	15 (6.0)
Lymphopenia	21 (8.5)	19 (7.7)
Non-hematologic TEAEs		
Infections and infestations	82 (33.1)	20 (8.1)
Nervous system disorders	60 (24.2)	8 (3.2)
Peripheral sensory neuropathy	15 (6.0)	2 (0.8)
General disorders and administration site conditions	101 (40.7)	16 (6.5)
Pyrexia	33 (13.3)	6 (2.4)
Fatigue	31 (12.5)	2 (0.8)
Asthenia	24 (9.7)	3 (1.2)
Peripheral edema	24 (9.7)	1 (0.4)
Gastrointestinal disorders	83 (33.5)	9 (3.6)
Diarrhea	40 (16.1)	2 (0.8)
Nausea	25 (10.1)	3 (1.2)
Constipation	14 (5.6)	0
Vomiting	14 (5.6)	2 (0.8)
Musculoskeletal and connective tissue disorders	67 (27.0)	15 (6.0)
Back pain	26 (10.5)	4 (1.6)
Arthralgia	20 (8.1)	3 (1.2)
Bone pain	13 (5.2)	2 (0.8)
Respiratory, thoracic, and mediastinal disorders	55 (22.2)	14 (5.6)
Dyspnea	29 (11.7)	5 (2.0)
Metabolism and nutrition disorders	37 (14.9)	9 (3.6)
Injury, poisoning, and procedural complications	30 (12.1)	10 (4.0)
Psychiatric disorders	26 (10.5)	3 (1.2)
Renal and urinary disorders	25 (10.1)	14 (5.6)
Investigations	24 (9.7)	7 (2.8)
Skin and subcutaneous tissue disorders	23 (9.3)	1 (0.4)
Vascular disorders	22 (8.9)	7 (2.8)
Cardiac disorders	18 (7.3)	8 (3.2)
Eye disorders	18 (7.3)	4 (1.6)

LOT line of therapy, TEAE treatment-emergent adverse event.